Yubo International Biotech Ltd. (YBGJ)

[Potse]

January 14 8-K...a couple of observations.....

The OTC Markets profile page needs to get fully updated, and a more investor friendly/updated corporate website needs to be deployed. But assuming the company executes on its plans, and becomes active in the investor relations side of being a public company, there should be a number of opportunities for very nice IR-activity through much of this year.

The stock has managed to get to the $3 price area with minimal buying interest and minimal IR assistance. Should be somewhat interesting to see what might happen if the news flow begins/intensifies as the operational activity increases.

A couple of observations from the January 14 8-K......

1) Based on the information in that filing, it looks like the earliest the company began generating its first revenues was in April 2020. Gross margin was over 91%, which is quite interesting because included in that revenue was 300 of its nebulizers (medical devices to deliver the inhalant). I have no idea if that margin percentage is just an aberration or if it is indicative of what YBGJ might generate going forward on its product-related revenue. Margin percentages anywhere close to that would be excellent.

2) Kind of interesting to note that on September 11, 2020, shortly before Lina Liu purchased control of the MAGAA shell, an individual investor (Cheung Ho Shun) made a pretty large investment in Platinum International Biotech (he purchased 1.5% of the company). Post reverse merger, his $750K investment equals 1,755,000 shares of YBGJ with a cost basis a little under 43 cents per share.